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Background: Palliative sedation (PS) is necessary in a significant percentage of patients
dying on an acute palliative care unit (PCU). Common indications are terminal restlessness,
pain and dyspnoea. On our PCU, terminal restlessness was the main indication for PS but
pain was the most prevalent symptom during admission. Because delirium is often drug
induced in terminal cancer patients and opioids are amongst the most frequently impli-
cated drugs, we hypothesised that the underlying pain problem and its treatment might
have been related to the need for sedation.
Patients and methods: To test this hypothesis, we did a retrospective analysis on the use of
medication with potential cognitive side-effects, focusing on analgesics, in 68 patients who
died on the PCU after PS and 89 patients who died without PS.
Results: Ultimately sedated patients used opioids in significantly higher doses; they were
more often treated with a rotation to another opioid and with amitriptyline. The dose of
opioids used at various time points between admission and death was strongly related
to the probability of PS.
Conclusions: Our findings support the hypothesis that, although pain was not the main
indication for PS, pain and its treatment might have been primarily related to the need
for palliative sedation in this patient cohort.
 2011 Elsevier Ltd. Open access under the Elsevier OA license.1. Introduction
Palliative sedation (PS) is the monitored use of medication
intended to induce varying states of unconsciousness, but
not death, in order to relieve refractory and unendurable
symptoms in patients in whom death is imminent.1 This im-
plies that PS is only justified when unendurable symptomst of Medical Oncology, Era
rlands. Tel.: +31 10 70419
(A.W. Oosten).
the Elsevier OA license.are present that cannot be controlled with appropriate
measures.
Common indications for PS are pain, terminal restlessness/
delirium/confusion and dyspnoea. In some reported series
deliriumorconfusion/restlessnesswas themost frequent indi-
cation for PS2–4 whilst in other series dyspnoea5,6 or pain7–9
were found to be the most frequent indications.smus University Medical Center, Daniel den Hoed Cancer Center,
06; fax: +31 10 7041003.
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acutepalliative care in auniversity cancerhospital in theNeth-
erlands has been reported by Rietjens et al.10 They described
157 patients who died at this unit, and studied differences be-
tween 68 sedated and 89 non-sedated patients. They found
that terminal restlessness was the most common indication
for PS (60%), followed by dyspnoea (46%) and pain (26%). Pain,
however, was the most prevalent symptom on admission (up
to 87%), and its prevalence remained high during admission –
both for patients who died after PS as for patients who were
not sedated before death. Prior to the onset of sedation, se-
dated patientsmore often suffered fromdeliriumas compared
to non-sedated patients at similar periods before death.
As it is known that delirium is often drug induced in ad-
vanced cancer patients and, more specifically, that opioids
are amongst the most frequently implicated drugs,11–14 it is
possible that the underlying pain problem and its treatment
were primarily related to the need for sedation. In this new
retrospective analysis, we therefore studied differences in
the use of medication with potential cognitive side-effects,
with special attention for opioids and other, adjuvant, drugs
used in the treatment of complex pain, between patients
who were ultimately sedated prior to death and patients dy-
ing without sedation.
2. Patients and methods
We conducted a new retrospective analysis of data from the
same cohort of patients that was studied by Rietjens et al.10
The cohort consisted of all patients who died on our specia-
lised acute palliative care unit (PCU) in a tertiary cancer hos-
pital in Rotterdam, The Netherlands between October 2001
and October 2005.
The main goal during admission to the PCU is to provide
symptom control for cancer patients with advanced disease.
Daily multidisciplinary meetings are held with medical oncol-
ogists, nurses, an anesthesiologist, a neurologist and a psychi-
atrist present; other specialists are consulted when needed.
Pain is treated stepwise following the WHO pain medica-
tion ladder.15 Of note, because many patients on the PCU
are admitted with complex pain problems, high doses of opi-
oids, opioid rotation, parenteral administration of opioids
and/or adjuvant analgesics are often needed. In patients with
severe pain, we generally use parenteral morphine or fentanyl
for titration, if possible subcutaneously. Doses are titrated
whilst closely monitoring the effect on pain and side-effects.
Patients are monitored for the development of delirium using
the Delirium Observation Screening (DOS) scale, a Dutch-
developed 13 point nurse observation scale filled out three
times daily.16 For all patients who score P3 points or when
delirium is suspected on clinical grounds, the psychiatrist is
consulted. In case of dose-limiting side-effects that cannot
be controlled with symptomatic therapy and/or inadequate
effect on pain, opioid rotation to another type of opioid is
used. We reserve the use of parenteral hydromorphone for
patients whose pain cannot be controlled with high doses of
other opioids, when dose-limiting side-effects occur related
to other opioids or when problems related to the administra-
tion of large volumes subcutaneously arise. In these circum-
stances, ketamine may also be used as an adjuvant drug.A decision to use palliative sedation in a dying patient is
discussed in a multidisciplinary meeting. In case of sedation,
opioids are continued at the dose level used at the start of the
sedation, according to (inter)national guidelines.
A detailed description of the data collection and analysis is
given in the original article.10
In summary, the database was built in four time frames:
admission (T0), 72–49 h before death (T1), 48–25 h before
death (T2) and 24–0 h before death (T3). Baseline variables
were scored on admission, other variables in the three time
frames prior to death. The start of palliative sedation was
not per se related to the time frames but could take place be-
tween admission and time of death.
Regarding medication, we studied the use of: acetamino-
phen/NSAIDs,opioids,ketamine,amitriptyline,anti-convulsants,
corticosteroids, benzodiazepines, anti-hypertensive drugs,
diuretics, anti-emetics and acid reflux/stomach medication.
In thecategoryofopioidswedifferentiatedvarious typesofopi-
oids in the time frames prior to death and registered rotations
to another type of opioid.
Per time frame, doses of all opioids administered (contin-
uous, slow release and immediate release products) were
recalculated to the morphine equivalent daily dose (MED)
per 24 h. This was done according to published equianalgesic
dose tables: oral morphine 60 mg/d = parenteral morphine
20 mg/d = transdermal fentanyl 25 mcg/h = parenteral fenta-
nyl 25 mcg/h = oral oxycodone 30 mg/d = oral hydromor-
phone 8 mg/d = parenteral hydromorphone 4 mg/d.17–19
Conversion rates for tramadol, methadone and epidurally or
intrathecally administered opioids are not included in these
tables. For tramadol we used a conversion rate of 4:1 (trama-
dol:morphine), according to results of a study by Wilder–
Smith in 1994.20 For oral methadone we used a conversion
factor of 1:4.7 (methadone:morphine), according to data from
a study by Walker et al.21 For epidurally or intrathecally
administered opioids no relevant studies could be found.
We therefore decided to use conversion factors of 1:30 (epidu-
ral:oral morphine) and 1:300 (intrathecal:oral morphine),
respectively, factors based on theory and clinical experience
of pain specialists from the department of anaesthesiology
in our hospital.2.1. Statistical analyses
Data were analysed using STATA version 10. Descriptive sta-
tistics were used to describe patients’ characteristics. Re-
ported p-values are two-tailed and p < 0.05 was considered
to be statistically significant. To assess the association be-
tween the MED and the probability of PS logistical regression
analysis was used. For each interval we calculated logistic
regression of sedation (yes or no) versus log (MED). So, we ob-
tained the probability of sedation for each MED-value and for
all time periods.3. Results
Patient characteristics of 68 sedated and 89 non-sedated pa-
tients are given in Table 1. In case of sedation, it was started
in the last 24 h before death in a majority of patients (68%).






N % N %
Male 31 46 40 45 0.87
Age median (range) 57 (27–89) 61 (25–80) 0.03
Primary tumour
Lung 15 22 12 13 0.19
Gastro-intestinal 14 21 5 6 <0.01
Breast 11 16 22 25 0.16
Genito-urinary tract 7 10 17 19 0.13
Head and neck 5 7 5 6 0.66
Melanoma 8 12 6 7 0.27
Sarcoma 5 7 7 8 0.91
Other/(A)CUP 3 4 15 17 0.02
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palliative sedation are shown in Table 2. There was a high
prevalence of pain in both groups.
One patient in the sedated group was excluded from fur-
ther analyses, because no information on used medication
could be found.
No statistically significant differences were found in the
percentage of patients using anti-convulsants, corticoste-
roids, anti-hypertensive drugs, diuretics, anti-emetics and
acid reflux/stomach medication in T0-T3. Significantly more
patients in the ultimately sedated group used benzodiaze-
pines at T0, 10/68 (22%) sedated versus 2/89 (3%) non-sedated
patients (p = 0.002). For T1–3 data could not be used as the
indication for benzodiazepines was not registered, so they
could then also be used for the purpose of PS.
The use of pain medication is shown in Fig. 1. No signifi-
cant differences were found in the percentage of patients
using WHO step 1 pain medication and opioids (Fig 1a). The
figure shows that the percentage of patients using WHO step
1 medication decreased with time, whilst the percentage of
patients using opioids increased in both groups.
Fig. 1b shows that sedated patients more frequently used
amitriptyline in T0–2. (p = 0.02, p = 0.002, p = 0.004, respec-
tively). Between T0 and T1 the percentage of patients using
ketamine in the ultimately sedated group increased fromTable 2 – Symptom prevalence on admission and indications fo
Sedated patients
N = 68





Indication for palliative sedation
Pain 18
Pain as the only indication for PS 7
Terminal restlessness 41
Dyspnoea 31
Other 104.5% to 13.4%, whereas it remained stable in the non-sedated
group (differences NS).
Fig. 1c shows that about 40% of the ultimately sedated pa-
tients used haloperidol in T1 and T2, whereas this percentage
was about 20% for the non-sedated group (p = 0.02 and
p = 0.034, respectively).
Variations regarding the use of specific types of opioids
and the various routes of administration were studied per
time frame. At T0, patients from the ultimately sedated group
and the non-sedated group used similar types of opioids.
Many patients were rotated from oral to parenteral opioids
during admission, but especially between T0 and T1, without
differences between the groups. Between T0 and T1, rotation
to another type of opioid was more often used in the group of
patients who were ultimately sedated than in the non-se-
dated group: in 30/68 pts (44%) and 19/89 pts (22%), respec-
tively (p < 0.005). In particular, more patients were set on
hydromorphone (9.3 versus 1.2%, p = 0.017) or spinal pain
medication (4.5 versus 1.2%, NS) during this period. There
were no significant differences in the use of opioid rotations
between sedated and non-sedated patients during the last
72 h of life.
The median morphine equivalent daily dose (MED) of opi-
oids in T0–3 for sedated and non-sedated patients is shown in




87 69 78 0.2
29 28 31 0.7
12 9 10 0.8






Fig. 1 – Differences in the use of pain medication and
haloperidol between sedated and non-sedated patients.
Fig. 2 – Median equianalgesic dose of opioids per time
frame.
Fig. 3 – Probability of PS in relation to the MED of opioids on
T0, logistic regression analysis.
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p < 0.001, respectively).
One patient was found to use extremely high doses of opi-
oids. Because the possibility of an error in noting the dose
could not be excluded, this patient was excluded for the anal-
yses on equianalgesic doses of opioids.
Fig. 3 shows the probability of dying with PS in relation to
the logarithm of the MED of opioids at T0 using logisticregression analysis. The figure shows that there was a strong
relationship between the dose of opioids at T0 and the prob-
ability of becoming sedated before death (p = 0.017). Similar
results were obtained for time frames T1 and T2 (p = 0.004)
and p < 0.001).
4. Discussion
PS is necessary in a significant percentage of patients dying
on an acute PCU.3,5 These patients suffer from treatment
refractory symptoms distressing them as well as their family
members and care givers. The setting in which PS is per-
formed, is therefore always difficult and stressful, making it
all the more important to better understand the trajectory
leading to PS and the factors that may influence it.
As mentioned in the introduction of this article, in some
settings delirium or terminal restlessness/confusion is the
main indication for PS whilst in others dyspnoea or pain is
the main indication. To our knowledge, studies on predictors
for the occurrence of refractory symptoms in the dying phase
have not been performed.
In our cohort of patients pain was one of the main indica-
tions for PS in 26% of patients, and the only indication in 10%
of patients – although pain was very prominent. This reflects
the fact that we have the facilities and the experience to treat
patientswith severeanddifficultpainproblems.However, pain
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need for PS as it is known that delirium is often drug induced.
Because in our cohort of patients, delirium/terminal restless-
ness was the main indication for PS, we studied differences
in medication with potential cognitive side-effects between
ultimately sedated patients and non-sedated patients. We
found some striking differences in the use of painmedication.
The ultimately sedated patients used opioids in significantly
higher doses; they were more often treated with a rotation to
another type of opioid – in some to hydromorphone – andwith
adjuvant amitriptyline. Furthermore, ketamine and spinal
medication were used more frequently, although differences
were not statistically significant. These results support our
hypothesis ofmoredifficult painproblems in theultimately se-
datedgroupcompared to thenon-sedatedpatients.Although it
is likely that sedated patients hadmore severe pain, we unfor-
tunately have no data to substantiate this as the severity of
pain was not registered in the database in this study period.
However, in our previous analyses in this same group of pa-
tients we already found indications to suggest a more aggres-
sive course of the underlying cancer in the sedated patients,
which is also compatiblewith the assumption ofmore difficult
pain problems in this group of patients.10 Thus, ultimately se-
dated patients are likely to have had more difficult pain prob-
lems, leading to more intense treatment with a higher risk of
terminal restlessness/delirium.
Differences in pharmacokinetics and pharmacodynamics
of pain medication between the groups may also be impor-
tant. It is possible that ultimately sedated patients had less
analgesic effects and/or more side-effects from the usedmed-
ication. Large inter-individual differences in the metabolism
of morphine have indeed been described22,23 and genetic var-
iability is assumed.24 Results of studies on the relation be-
tween morphine metabolites and delirium in cancer
patients are conflicting, however.25–28 Furthermore, a recently
published large European study could not find an association
between genetic variability and opioid dose.29 More research
on the effects of pharmacokinetic and pharmacogenetic var-
iability on analgesic and side-effects of opioids is needed.
To our knowledge, this is the first study addressing the
possible role of pharmacological interventions for the treat-
ment of complex pain in the need for PS in a group of termi-
nally ill cancer patients. Although the retrospective design of
our study is an important limitation, our findings indicate
that more insight in the pathophysiologic mechanisms of
refractory symptoms in the dying phase is needed.
In conclusion, our findings suggest that ultimately sedated
patients had more difficult pain problems and/or had a dis-
turbed dose–effect relationship for opioids. The more inten-
sive treatment of these patients could have led to a higher
rate of treatment refractory delirium/terminal restlessness,
sometimes necessitating PS. Although pain was not the main
indication for PS in our cohort of patients, its treatment might
very well have been related to the need for PS. This empha-
sises the need for more individualised treatment schemes,
to minimise the risk of adverse events.
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